BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29891115)

  • 1. A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival.
    Doosti-Irani A; Holakouie-Naieni K; Rahimi-Foroushani A; Mansournia MA; Haddad P
    Crit Rev Oncol Hematol; 2018 Jul; 127():80-90. PubMed ID: 29891115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
    Huang TC; Hsu CH; Lin CC; Tu YK
    Jpn J Clin Oncol; 2015 Nov; 45(11):1023-8. PubMed ID: 26246479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies.
    Zhang SS; Yang H; Xie X; Luo KJ; Wen J; Bella AE; Hu Y; Yang F; Fu JH
    Dis Esophagus; 2014 Aug; 27(6):574-84. PubMed ID: 23621119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
    Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
    Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
    Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
    Liu T; Ding S; Dang J; Wang H; Chen J; Li G
    Radiat Oncol; 2019 Oct; 14(1):176. PubMed ID: 31619265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma.
    McDowell LJ; Huang SH; Xu W; Che J; Wong RKS; Brierley J; Kim J; Cummings B; Waldron J; Bayley A; Hansen A; Witterick I; Ringash J
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):186-195. PubMed ID: 28258892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
    Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
    BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
    Hamamoto Y; Mizusawa J; Katayama H; Nakamura K; Kato K; Tsubosa Y; Ishikura S; Igaki H; Shinoda M; Fukuda H; Kitagawa Y; Ando N
    Jpn J Clin Oncol; 2016 Apr; 46(4):389-92. PubMed ID: 26830150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
    Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
    World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
    Athauda A; Watkins D; Mohammed K; Chau I; Starling N; Rao S; Tait D; Aitken K; Cunningham D
    Anticancer Res; 2018 Oct; 38(10):5943-5949. PubMed ID: 30275223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.